Saturday 17 October 2026
Export PFE’s income statement to Excel — free account
Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
29.58
0.14
+0.48%
Follow PFE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
26.76 | 9.68 | 22.03 | 12.77 | 21.40 | 15.14 | 9.20 | 82.58 | 18.70 | 18.31 |
Piotroski F-Score |
6 | 6 | 5 | 6 | 6 | 7 | 6 | 3 | 8 | 6 |
Altman Z-Score |
2.19 | 2.57 | 2.82 | 2.35 | 2.69 | 3.62 | 3.76 | 1.70 | 2.02 | 2.03 |
P/S ratio |
3.61 | 3.93 | 5.96 | 5.06 | 4.91 | 4.07 | 2.84 | 2.82 | 2.36 | 2.26 |
P/FCF ratio |
13.48 | 14.23 | 17.76 | 20.45 | 17.97 | 11.38 | 11.39 | 42.00 | 16.63 | 17.10 |
Altman Z″-Score (non-manufacturers) |
2.70 | 3.32 | 3.51 | 2.63 | 3.39 | 3.97 | 4.59 | 2.30 | 3.14 | 3.19 |
Beneish M-Score |
(2.68) | (2.39) | (2.88) | (2.63) | (2.52) | (1.98) | (2.34) | (2.37) | (2.71) | (2.52) |
P/Operating CF |
31.56 | 29.11 | 51.32 | 54.92 | 36.35 | 55.92 | 33.50 | 32.02 | 22.36 | 26.46 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 28 |
P/B ratio |
3.19 | 2.88 | 3.81 | 3.26 | 3.22 | 4.27 | 3.00 | 1.88 | 1.70 | 1.63 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 106.42 | 245.28 | 0.00 | 0.00 | 0.00 |
EV/Sales |
4.07 | 4.37 | 6.52 | 6.10 | 5.57 | 4.16 | 2.97 | 3.81 | 3.05 | 3.08 |
EV/EBITDA |
12.00 | 11.50 | 22.51 | 20.02 | 17.95 | 13.73 | 7.36 | 29.99 | 9.99 | 9.25 |
EV/Operating CF |
13.27 | 13.68 | 16.81 | 19.82 | 16.11 | 10.38 | 10.27 | 26.09 | 15.23 | 16.46 |
EV/FCF |
15.19 | 15.85 | 19.43 | 24.64 | 20.40 | 11.63 | 11.91 | 56.83 | 21.49 | 23.28 |
Quick Ratio |
0.84 | 0.93 | 0.84 | 0.44 | 0.78 | 1.00 | 0.80 | 0.51 | 0.74 | 0.69 |
Current Ratio |
1.25 | 1.35 | 1.57 | 0.88 | 1.35 | 1.40 | 1.22 | 0.91 | 1.17 | 1.16 |
Net Debt/EBITDA |
1.35 | 1.18 | 1.94 | 3.41 | 2.14 | 0.30 | 0.32 | 7.82 | 2.26 | 2.46 |
Debt/Assets |
24.52% | 25.32% | 26.18% | 31.12% | 25.83% | 21.18% | 18.17% | 31.74% | 30.16% | 31.13% |
Debt/Equity |
0.70 | 0.61 | 0.65 | 0.82 | 0.63 | 0.50 | 0.37 | 0.81 | 0.73 | 0.75 |
Asset Turnover |
0.31 | 0.31 | 0.25 | 0.25 | 0.26 | 0.48 | 0.53 | 0.28 | 0.29 | 0.30 |
Operating CF/Net income |
2.24 | 0.79 | 1.42 | 0.79 | 1.57 | 1.48 | 0.93 | 4.11 | 1.59 | 1.51 |
Capex/Depreciation |
(0.35) | (0.35) | (0.35) | (0.43) | (0.59) | (0.52) | (0.64) | (0.62) | (0.41) | (0.40) |
| 11.56% | 32.42% | 16.48% | 25.20% | 14.43% | 31.19% | 36.19% | 2.29% | 9.03% | 8.87% | |
| 4.26% | 12.41% | 6.73% | 9.80% | 5.69% | 13.09% | 16.57% | 1.00% | 3.65% | 3.69% | |
ROIC |
9.03% | 9.01% | 4.09% | 3.96% | 5.66% | 14.32% | 20.52% | 0.54% | 5.86% | 6.45% |
Return on Tangible Assets |
34.11% | 86.69% | 35.46% | 189.25% | 40.01% | 68.89% | 123.54% | 14.63% | 31.18% | 30.80% |
Average Days of Receivables |
56.83 | 57.11 | 71.75 | 60.43 | 69.34 | 51.54 | 39.51 | 70.89 | 65.76 | 69.26 |
Research and Development Expense of Revenue |
14.94% | 14.62% | 19.01% | 20.50% | 20.91% | 12.74% | 11.30% | 17.93% | 17.01% | 16.68% |
Selling, General and Administrative Expense of Revenue |
28.10% | 28.17% | 30.89% | 31.11% | 27.84% | 15.63% | 13.52% | 24.80% | 23.15% | 22.04% |
Intangible Assets out of Total Assets |
0.62 | 0.61 | 0.56 | 0.49 | 0.51 | 0.41 | 0.48 | 0.59 | 0.58 | 0.60 |
Share Based Compensation of Revenue |
1.31% | 1.60% | 2.26% | 1.68% | 1.81% | 1.45% | 0.86% | 0.88% | 1.38% | 1.28% |
Graham Net Nets |
(0.38) | (0.29) | (0.19) | (0.34) | (0.27) | (0.13) | (0.17) | (0.56) | (0.50) | (0.55) |
Graham Number |
16.08 | 31.05 | 21.43 | 27.31 | 21.03 | 34.84 | 46.30 | 11.32 | 22.33 | 21.62 |
Earnings Yield |
3.74% | 10.33% | 4.54% | 7.83% | 4.67% | 6.60% | 10.87% | 1.21% | 5.35% | 5.46% |
Free Cash Flow Yield |
7.42% | 7.03% | 5.63% | 4.89% | 5.56% | 8.79% | 8.78% | 2.38% | 6.01% | 5.85% |
Revenue per Share |
8.68 | 8.80 | 6.95 | 7.35 | 7.50 | 14.51 | 18.04 | 10.55 | 11.23 | 11.01 |
Operating CF per Share |
2.66 | 2.81 | 2.70 | 2.26 | 2.59 | 5.82 | 5.22 | 1.54 | 2.25 | 2.06 |
Capex per Share |
(0.33) | (0.37) | (0.36) | (0.44) | (0.50) | (0.48) | (0.58) | (0.69) | (0.51) | (0.46) |
Free Cash Flow per Share |
2.33 | 2.44 | 2.33 | 1.82 | 2.10 | 5.33 | 4.64 | 0.85 | 1.74 | 1.60 |
Cash per Share |
2.93 | 3.35 | 3.21 | 1.73 | 2.20 | 5.55 | 4.05 | 2.25 | 3.62 | 2.39 |
Shareholders Equity per Share |
9.83 | 12.00 | 10.86 | 11.39 | 11.43 | 13.83 | 17.10 | 15.82 | 15.62 | 15.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.83 | 12.00 | 10.86 | 11.39 | 11.43 | 13.83 | 17.10 | 15.82 | 15.62 | 15.27 |
Free Cash Flow |
14,193.00 | 14,585.00 | 13,691.00 | 10,124.00 | 11,638.00 | 29,869.00 | 26,031.00 | 4,793.00 | 9,835.00 | 9,075.00 |
Working Capital |
7,834.00 | 10,714.00 | 18,068.00 | (4,501.00) | 9,147.00 | 17,022.00 | 9,121.00 | (4,461.00) | 7,363.00 | 5,914.00 |
Capital Expenditures |
(1,999.00) | (2,217.00) | (2,136.00) | (2,464.00) | (2,765.00) | (2,711.00) | (3,236.00) | (3,907.00) | (2,909.00) | (2,629.00) |
Net Current Asset Value |
(72,827.00) | (59,000.00) | (45,738.00) | (71,345.00) | (55,689.00) | (44,320.00) | (50,029.00) | (93,880.00) | (74,541.00) | (78,487.00) |
EV/EBIT |
17.69 | 16.75 | 46.91 | 37.18 | 28.13 | 17.40 | 8.40 | 177.45 | 15.64 | 13.53 |
Capex to Sales |
0.04 | 0.04 | 0.05 | 0.06 | 0.07 | 0.03 | 0.03 | 0.07 | 0.05 | 0.04 |
Price to Operating Income |
15.70 | 15.04 | 42.87 | 30.85 | 24.79 | 17.02 | 8.03 | 131.17 | 12.11 | 9.93 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.43 | 0.45 | 0.46 | 0.44 | 0.34 | 0.35 | 0.31 | 0.33 | 0.38 | 0.34 |
Cash ROIC |
11.85% | 10.79% | 11.01% | 8.08% | 10.07% | 20.32% | 16.85% | 2.76% | 5.67% | 5.49% |
Accounts Receivable Turnover |
6.44 | 6.39 | 5.03 | 5.53 | 5.67 | 8.38 | 9.02 | 5.29 | 5.53 | 5.36 |
Accounts Payable Turnover |
3.02 | 2.44 | 1.93 | 1.88 | 2.08 | 6.25 | 5.55 | 3.69 | 2.89 | 2.96 |
Inventory Turnover |
1.72 | 1.56 | 1.19 | 1.11 | 1.12 | 3.61 | 3.81 | 2.60 | 1.70 | 1.49 |
Average Days of Payables |
134.36 | 151.36 | 189.83 | 176.16 | 184.26 | 66.06 | 72.36 | 98.15 | 115.18 | 119.04 |
Days of Inventory on Hand |
200.92 | 246.35 | 304.93 | 320.32 | 345.04 | 107.28 | 95.45 | 149.03 | 221.87 | 242.03 |
Average Receivables |
8,200.50 | 8,223.00 | 8,123.00 | 7,398.50 | 7,342.50 | 9,696.00 | 11,215.50 | 11,259.00 | 11,514.50 | 11,668.50 |
Average Payables |
4,078.00 | 4,596.00 | 4,665.00 | 4,280.50 | 4,085.00 | 4,930.50 | 6,193.50 | 6,759.50 | 6,171.50 | 5,436.50 |
Average Inventory |
7,148.00 | 7,180.50 | 7,543.00 | 7,288.00 | 7,544.00 | 8,539.50 | 9,020.00 | 9,585.00 | 10,520.00 | 10,752.50 |
Average Assets |
169,498.00 | 171,706.00 | 165,609.50 | 163,508.00 | 160,911.50 | 167,852.50 | 189,340.50 | 211,853.00 | 219,948.50 | 210,778.00 |
Average Common Equity |
62,394.00 | 65,725.50 | 67,687.50 | 63,584.00 | 63,450.50 | 70,467.50 | 86,689.50 | 92,602.50 | 88,892.50 | 87,636.00 |
Columns are period end dates